Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease

L-Dopa continues to be the gold drug in Parkinson's disease (PD) treatment from 1967. The failure to translate successful results from preclinical to clinical studies can be explained by the use of preclinical models which do not reflect what happens in t

Detalles Bibliográficos
Autores: Herrera, A., Muñoz, P., Paris, I., Díaz-Veliz, G., Mora, S., Inzunza, J., Hultenby, K., Cardenas, C., Jaña, F., Raisman-Vozari, R., Gysling, K., Abarca, J., Steinbusch, H. W., Segura-Aguilar, J.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:Chile
Idioma:inglés
OAI Identifier:oai:repositorio.anid.cl:10533/240132
Acceso en línea:https://hdl.handle.net/10533/240132
Access Level:acceso abierto
id CL_6dfd519e3affb27a9a498ab20751f3be
oai_identifier_str oai:repositorio.anid.cl:10533/240132
network_acronym_str CL
network_name_str Chile
repository_id_str
spelling Segura-Aguilar, J.Steinbusch, H. W.Abarca, J.Gysling, K.Raisman-Vozari, R.Jaña, F.Cardenas, C.Hultenby, K.Inzunza, J.Mora, S.Díaz-Veliz, G.Paris, I.Muñoz, P.Herrera, A.201610.1007/s00018-016-2182-5https://hdl.handle.net/10533/240132http://purl.org/coar/access_right/c_abf2Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's diseaseHerrera, A.Muñoz, P.Paris, I.Díaz-Veliz, G.Mora, S.Inzunza, J.Hultenby, K.Cardenas, C.Jaña, F.Raisman-Vozari, R.Gysling, K.Abarca, J.Steinbusch, H. W.Segura-Aguilar, J.2020-03-11T20:33:58Z2022-07-08T17:04:17Z2020-03-11T20:33:58Z2022-07-08T17:04:17Z2016L-Dopa continues to be the gold drug in Parkinson's disease (PD) treatment from 1967. The failure to translate successful results from preclinical to clinical studies can be explained by the use of preclinical models which do not reflect what happens in tFONDAPFONDAP15150012WOS:000382390600011https://hdl.handle.net/10533/240132eng10.1007/s00018-016-2182-5https://doi.org/10.1007/s00018-016-2182-5Atribución-NoComercial-SinDerivadas 3.0 Chilehttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/info:eu-repo/semantics/openAccessAminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's diseaseCell Mol Life SciArticuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttps://hdl.handle.net/10533/240132FONDAPhttp://purl.org/coar/resource_type/c_2df8fbb110533/240132oai:repositorio.anid.cl:10533/2401322023-07-24 19:18:41.418https://repositorio.anid.clRepositorio ANIDaletelier@anid.cl
dc.title.none.fl_str_mv Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
dc.title.journal.none.fl_str_mv Cell Mol Life Sci
title Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
spellingShingle Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
Herrera, A.
title_short Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
title_full Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
title_fullStr Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
title_full_unstemmed Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
title_sort Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease
dc.creator.none.fl_str_mv Herrera, A.
Muñoz, P.
Paris, I.
Díaz-Veliz, G.
Mora, S.
Inzunza, J.
Hultenby, K.
Cardenas, C.
Jaña, F.
Raisman-Vozari, R.
Gysling, K.
Abarca, J.
Steinbusch, H. W.
Segura-Aguilar, J.
author Herrera, A.
author_facet Herrera, A.
Muñoz, P.
Paris, I.
Díaz-Veliz, G.
Mora, S.
Inzunza, J.
Hultenby, K.
Cardenas, C.
Jaña, F.
Raisman-Vozari, R.
Gysling, K.
Abarca, J.
Steinbusch, H. W.
Segura-Aguilar, J.
author_role author
author2 Muñoz, P.
Paris, I.
Díaz-Veliz, G.
Mora, S.
Inzunza, J.
Hultenby, K.
Cardenas, C.
Jaña, F.
Raisman-Vozari, R.
Gysling, K.
Abarca, J.
Steinbusch, H. W.
Segura-Aguilar, J.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
description L-Dopa continues to be the gold drug in Parkinson's disease (PD) treatment from 1967. The failure to translate successful results from preclinical to clinical studies can be explained by the use of preclinical models which do not reflect what happens in t
publishDate 2016
dc.date.issued.none.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2020-03-11T20:33:58Z
2022-07-08T17:04:17Z
dc.date.available.none.fl_str_mv 2020-03-11T20:33:58Z
2022-07-08T17:04:17Z
dc.type.none.fl_str_mv Articulo
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.openaire.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.folio.none.fl_str_mv 15150012
dc.identifier.idwos.none.fl_str_mv WOS:000382390600011
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10533/240132
identifier_str_mv 15150012
WOS:000382390600011
url https://hdl.handle.net/10533/240132
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.doi.none.fl_str_mv 10.1007/s00018-016-2182-5
dc.relation.uri.none.fl_str_mv https://doi.org/10.1007/s00018-016-2182-5
dc.rights.none.fl_str_mv Atribución-NoComercial-SinDerivadas 3.0 Chile
http://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rights.driver.none.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 3.0 Chile
http://creativecommons.org/licenses/by-nc-nd/3.0/cl/
eu_rights_str_mv openAccess
repository.name.fl_str_mv Repositorio ANID
repository.mail.fl_str_mv aletelier@anid.cl
_version_ 1843518584948523008
score 15.812429

Similares en LA Referencia